Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$70.57 USD
+0.20 (0.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $70.64 +0.07 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth B Momentum D VGM
Income Statements
Fiscal Year end for Ligand Pharmaceuticals Incorporated falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 131 | 196 | 277 | 186 | 120 |
Cost Of Goods | 11 | 53 | 62 | 30 | 11 |
Gross Profit | 121 | 143 | 215 | 156 | 109 |
Selling & Adminstrative & Depr. & Amort Expenses | 109 | 140 | 136 | 130 | -698 |
Income After Depreciation & Amortization | 12 | 3 | 79 | 26 | 807 |
Non-Operating Income | 52 | 35 | -12 | -9 | 25 |
Interest Expense | 1 | 2 | 20 | 27 | 36 |
Pretax Income | 64 | 36 | 47 | -11 | 797 |
Income Taxes | 10 | 41 | -10 | -8 | 167 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 54 | -5 | 57 | -3 | 629 |
Extras & Discontinued Operations | -2 | -28 | 0 | 0 | 0 |
Net Income (GAAP) | 52 | -33 | 57 | -3 | 629 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 47 | 55 | 147 | 78 | 871 |
Depreciation & Amortization (Cash Flow) | 35 | 52 | 68 | 53 | 63 |
Income After Depreciation & Amortization | 12 | 3 | 79 | 26 | 807 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 17.76 | 16.87 | 17.25 | 16.19 | 19.76 |
Diluted EPS Before Non-Recurring Items | 2.91 | 1.94 | 4.65 | 3.13 | 2.11 |
Diluted Net EPS (GAAP) | 2.94 | -1.98 | 3.31 | -0.18 | 31.85 |
Fiscal Year end for Ligand Pharmaceuticals Incorporated falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 28.10 | 32.87 | 26.37 | 43.98 |
Cost Of Goods | NA | 1.64 | 3.49 | 1.67 | 3.72 |
Gross Profit | NA | 26.46 | 29.38 | 24.70 | 40.26 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 29.82 | 26.31 | 26.68 | 26.06 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.36 | 3.07 | -1.98 | 14.20 |
Non-Operating Income | NA | 20.59 | -15.22 | 5.44 | 41.57 |
Interest Expense | NA | 0.13 | 0.00 | 0.28 | 0.24 |
Pretax Income | NA | 17.10 | -12.14 | 3.17 | 55.54 |
Income Taxes | NA | -1.09 | -1.87 | 0.88 | 11.92 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 18.19 | -10.27 | 2.29 | 43.61 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | -1.67 |
Net Income (GAAP) | NA | 18.19 | -10.27 | 2.29 | 41.95 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 17.68 | 17.38 | 17.73 | 17.97 |
Diluted EPS Before Non-Recurring Items | NA | 0.79 | 0.71 | 1.10 | 1.96 |
Diluted Net EPS (GAAP) | NA | 1.07 | -0.59 | 0.13 | 2.33 |